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Immune-mediated diseases in dogs constitute a large group of disorders with the common 
attribute that they are caused by dysfunctions in the immune system. Broadly they can 
be classified into immunodeficiency disorders, allergies, and autoimmune diseases. 
Earlier studies have suggested that dogs of the breed Nova Scotia duck tolling retriever 
(NSDTR) are at increased risk of developing immune-mediated disorders. Two disorders 
have received particular attention: immune-mediated rheumatic disease (IMRD) and 
steroid-responsive meningitis-arteritis (SRMA). The major aims of this thesis were to 1) 
determine the incidence of immune-mediated disease in NSDTRs, 2) identify genetic risk 
factors for IMRD and SRMA, and 3) investigate the occurrence of different 
autoantibodies in dogs with autoimmune disease.  
Data from Agria Pet Insurance were used to estimate incidence of disease. Incidence 
of different immune-mediated diseases in NSDTRs was compared with that in other dog 
breeds. In general, the incidence for autoimmune diseases was three times higher in 
NSDTRs compared to other breeds. For IMRD and SRMA, the incidences were >10 
times higher.  
Both IMRD and SRMA are complex genetic diseases and several genetic loci 
associated with the respective disease have been identified by our research group. We 
performed a detailed analysis of these loci and found 11 genes with altered gene 
expression associated with IMRD or SRMA. The majority of these genes were associated 
with either IMRD or with SRMA only, but one gene (AP3B2) showed association to both 
diseases.  
Autoantibodies are important hallmarks of autoimmune diseases, including IMRD. In 
the studies presented in this thesis, different methods were used to identify the 
autoantibody targets in dogs that were positive for antinuclear autoantibodies. Both 
previously reported and new canine autoantibodies were found. The interleukin 
enhancer-binding factors 2 and 3 (ILF2 and ILF3) appear to be common autoantibody 
targets in IMRD patients. These autoantibodies have not previously been described in 
dogs and have the potential to be used as diagnostic markers for canine systemic 
autoimmune disease.  
Keywords: Antinuclear antibodies, autoimmunity, dog, gene expression, ILF2, ILF3, 
immune-mediated rheumatic disease, Nova Scotia duck tolling retriever, steroid-
responsive meningitis-arteritis, systemic lupus erythematosus.  
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Abstract 
 
 
Immunmedierade sjukdomar hos hund består av en stor grupp av olika åkommor. 
Gemensamt är att de orsakas av defekter i immunförsvaret. Generellt kan de delas in i 
immunbristsjukdomar, allergier och autoimmuna sjukdomar. Tidigare studier har antytt 
att hundar av rasen Nova Scotia duck tolling retriever (kallade tollare) har en ökad risk 
att utveckla immunmedierade sjukdomar. Det är framförallt två sjukdomar som 
uppmärksammats hos rasen: immunmedierad reumatisk sjukdom (IMRD) och steroid-
responsiv meningit-arterit (SRMA). De huvudsakliga syftena med denna avhandling var 
att 1) beskriva incidensen av immunmedierade sjukdomar hos tollare, 2) identifiera 
genetiska riskfaktorer för IMRD och SRMA hos tollare och 3) undersöka förekomst av 
olika autoantikroppar hos hundar med autoimmun sjukdom.  
Data från Agria Djurförsäkring användes för att uppskatta sjukdomsincidens. 
Incidensen av olika immunmedierade sjukdomar hos tollare undersöktes och jämfördes 
med incidensen hos hundar av andra raser. Autoimmuna sjukdomar var tre gånger 
vanligare hos tollare jämfört med andra hundraser. Incidensen för IMRD och SRMA var 
>10 gånger högre.  
Både IMRD och SRMA är komplexa genetiska sjukdomar. Flera regioner i arvsmas-
san associerade med dessa sjukdomar har tidigare identifierats. Vi utförde en detaljerad 
uppföljningsanalys av dessa regioner och hittade 11 gener associerade med IMRD eller 
SRMA som visade förändrat genuttryck. De flesta av dessa gener var associerade med 
bara en av sjukdomarna, men en gen (AP3B2) var associerad med båda sjukdomarna.  
Autoantikroppar är viktiga kännetecken för autoimmuna sjukdomar såsom IMRD. I 
studierna som presenteras i denna avhandling användes olika metoder för att detektera 
de målstrukturer som antinukleära autoantikropparna är riktade mot. Både tidigare 
beskrivna och nya autoantikroppar hos hund identifierades. Autoantikroppar mot 
interleukin enhancer-binding factor 2 och 3 (ILF2 och ILF3) var vanligt förekommande 
hos hundar med IMRD. Dessa autoantikroppar har inte beskrivits tidigare hos hund och 
har potential att kunna användas som diagnostiska markörer för systemisk autoimmun 
sjukdom hos hund. 
Nyckelord: Antinukleära antikroppar, autoimmunitet, genuttryck, hund, ILF2, ILF3, 
immunmedierad reumatisk sjukdom, Nova Scotia duck tolling retriever, steroid-
responsiv meningit-arterit, systemisk lupus erythematosus.  
Författarens adress: Hanna Bremer, SLU, Institutionen för kliniska vetenskaper,  
Box 7054, 750 07 Uppsala, Sweden  
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ANA Antinuclear antibodies 
ANAH Antinuclear antibody positive with a homogenous pattern 
ANAS Antinuclear antibody positive with a speckled pattern  
CLIFT Critidia luciliae indirect immunofluorescence test 
dsDNA Double stranded DNA 
DYAR Dog years at risk 
ELISA Enzyme-linked immunosorbent assay 
GWAS Genome-wide association study 
HEp-2 Human epithelial-2 
IIF Indirect immunofluorescence 
ILF2 Interleukin enhancer-binding factor 2 
ILF3 Interleukin enhancer-binding factor 3 
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MHC Major histocompatibility complex 
NFAT Nuclear factor of activated T-cells 
NSDTR Nova Scotia duck tolling retriever 
OR Odds ratio 
RBMX RNA-binding motif protein, X chromosome 
RNP Ribonucleoproteins 
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SLE Systemic lupus erythematosus 
Sm Smith antigen 
SNP Single nucleotide polymorphism 
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The immune system consists of a wide number of tissues, cells, and molecules 
that protect the body against foreign substances. The mechanisms that protect 
the body, the immune response, also have the potential to cause tissue injury and 
disease. Immune-mediated disorders develop when the immune system either 
fails to respond adequately (immunodeficiency), responds with increased 
magnitude against foreign substances that are not by themselves harmful 
(allergy), or responds to self-molecules (autoimmune disease). These varying 
disorders affect both humans and animals, including dogs. The studies included 
in this thesis are primarily focused on dogs with signs of autoimmune disease, 
specifically dogs of the breed Nova Scotia duck tolling retriever (NSDTR). This 
breed has previously been reported to be affected by a number of immune-
mediated diseases at unknown frequencies (Hansson-Hamlin & Lilliehöök, 
2013; Hansson-Hamlin & Lilliehöök, 2009; Anfinsen et al., 2008; Hughes et al., 
2007; Redman, 2002; Burton et al., 1997). In this thesis, the incidence of 
different immune-mediated diseases in NSDTRs is presented and it is shown that 
this breed is predisposed to autoimmune diseases. Several genetic risk factors 
for immune-mediated disease in NSDTRs were identified. Finally, canine sera 
were investigated for the occurrence of different autoantibodies – important 
diagnostic markers – and autoantibodies not previously described in dogs were 
discovered.  
 
  
1 Introduction 
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2.1 The immune response and immune-mediated 
disorders 
The immune response can be divided into the innate and the adaptive immune 
response (Abbas et al., 2017). The innate immune response is the body’s first 
response against a foreign substance. It is fast, unspecific, and has no memory. 
It consists of physical and chemical barriers (e.g. skin and antimicrobial 
substances), mechanical processes (e.g. cilia in airways), some blood proteins 
(e.g. components of the complement system), normal microbial flora, and some 
types of immune-cells and their products (e.g. phagocytic cells). If a foreign 
substance is not kept back or eradicated by the innate immune response, it will 
encounter the adaptive immune response. The adaptive immune response is 
specific and can respond to an infection with increased magnitude. It is rather 
slow, but has memory, and if infected again by the same pathogen, the response 
will be rapid. The main components of the adaptive immune response are 
lymphocytes and their products, such as cytokines and antibodies. Antibodies 
work in many ways to combat infections, by, for example, neutralizing toxins, 
opsonisation, and complement activation (Lu et al., 2017). 
There are several ways in which immune-mediated disorders may be 
classified (Day, 2008; McGonagle & McDermott, 2006; Pedersen, 1999). 
Broadly, they can be classified into immunodeficiency, allergy, and autoimmune 
disease. Sometimes immune system neoplasia is also included. Immuno-
deficiency diseases are characterized by an absent or compromised immune 
response. Allergies are caused by hypersensitivity to environmental factors. 
Allergic diseases, in particular with skin involvement, are common disorders in 
dogs (Wiles et al., 2017; O'Neill et al., 2014b). Autoimmune diseases develop 
as a loss of tolerance against self-molecules.  
2 Background 
 
 
18 
A primary or idiopathic autoimmune response develops in the absence of an 
underlying cause (Day, 2008). A secondary autoimmune reaction is more 
common and can develop as a response to, for example, infections, neoplasia, 
and certain drugs. In reality, it can be difficult to differentiate between primary 
and secondary autoimmunity, since underlying factors may remain unidentified. 
Indications of a primary autoimmune aetiology are: association to the major 
histocompatibility complex (MHC) class II genes, lymphocytic infiltration of 
target organs, presence of autoantibodies, and response to immunosuppressive 
drugs, although these factors alone do not prove that a disease is autoimmune 
(Rose & Bona, 1993).  
2.2 Autoimmune diseases in dogs and humans 
Autoimmune diseases can be organ specific or systemic, involving many organ 
systems. An example of an organ specific autoimmune disease that affects both 
dogs and humans is myasthenia gravis (Meriggioli & Sanders, 2009; Dewey et 
al., 1997). Systemic lupus erythematosus (SLE) is the classic example of a 
systemic autoimmune disease, well described in both humans (D'Cruz et al., 
2007)  and dogs (Fournel et al., 1992; Bennett, 1987; Grindem & Johnson, 1983; 
Lewis et al., 1965). One of the hallmarks of SLE is the occurrence of 
autoantibodies directed at different structures in the cell nucleus. These diverse 
autoantibodies are called antinuclear antibodies, commonly referred to as ANA 
(Tan, 1989).  
The diagnosis of autoimmune and other immune-mediated diseases is based 
on history, clinical signs, exclusion of other disorders, and for some diseases, 
specific tests. In human medicine, a diagnosis of an autoimmune disease is often 
based on a set of standardised criteria involving symptoms and laboratory 
abnormalities, as for example in human SLE (Petri et al., 2012; Hochberg, 1997; 
Tan et al., 1982). A consistent definition of a disease facilitates research and 
makes comparisons of different studies feasible. However, there is often 
considerable overlap between different immune-mediated and autoimmune 
diseases with respect to diagnostic findings and clinical signs (McGonagle & 
McDermott, 2006), and individual patients are not always easy to classify. In 
veterinary medicine, well-established disease criteria for autoimmune diseases 
are often lacking, which is a research limitation.  
2.2.1 Epidemiology 
In epidemiology, disease frequency is measured to identify populations at 
increased risk for a disease; this can indicate a genetic predisposition. Increased 
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awareness of disease frequency and predisposition in different dog breeds can 
assist in breeding and research prioritisations (O'Neill et al., 2014a). Disease 
frequency (morbidity) can be measured as prevalence (the proportion of existing 
cases in a population), as incidence proportion, and as incidence rate. Incidence 
rate is the number of new cases per population at risk in a given time period 
(Rothman, 2012).  
Many large and population based studies estimating the disease frequency of 
autoimmune disorders in humans are published, but equivalent studies in dogs 
are scarce. As separate entities, autoimmune disorders can be considered rare, 
but as a group they are common with an approximate prevalence of 5% in 
humans (Hayter & Cook, 2012; Jacobson et al., 1997). Estimates of frequencies 
for autoimmune diseases in dogs are harder to obtain, partly because of the lack 
of standardised criteria, as discussed earlier. A recent study by Wiles et al. 
(2017) estimated the overall prevalence of disease in UK purebred dogs from 
owner reported data. The proportion of autoimmune disorders reported in that 
study was 1.67%. This is likely an underestimate due to underreporting of minor 
conditions and because some autoimmune disorders are probably included in 
other disease categories. In humans, autoimmune diseases are more common in 
females than in males (Hayter & Cook, 2012; Whitacre et al., 1999; Jacobson et 
al., 1997). Although suggested by some (Pedersen, 1999; Quimby et al., 1980), 
a female predisposition is not as obvious in dogs (Sundburg et al., 2016); this 
may at least partly be explained by neutering practises. Autoimmune diseases 
often co-exist with other autoimmune diseases in humans (Cooper et al., 2009) 
and both human and canine patients with autoimmune disease also have a higher 
risk of developing some types of cancers (Keller, 1992; Pettersson et al., 1992). 
Clustering within families also occurs. This is also evident in dogs where some 
breeds and lines appear to have a higher incidence of autoimmune disease than 
others (Wiles et al., 2017; Day, 2008; Pedersen, 1999). Epidemiological studies 
can provide important information about risk factors and predisposition, but it 
should be noted that they do not prove what cause disease, since association is 
not the same as causation.   
2.2.2 Genetics  
Autoimmune diseases are more common in certain dog breeds and in some 
families (Wiles et al., 2017; Pedersen, 1999; Day & Penhale, 1992), strongly 
suggesting underlying genetic factors. Most autoimmune diseases segregate 
within families, but not according to a Mendelian inheritance pattern typical for 
monogenic disorders. Instead, the inheritance pattern for most autoimmune 
diseases is complex, in which changes (i.e. mutations) in multiple genes 
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contribute to disease susceptibility, and environmental factors contribute to, or 
trigger, development of disease (Marson et al., 2015; Rosenblum et al., 2015). 
The majority of diseases in dogs are complex (O'Neill et al., 2014b).  
The MHC genes are strongly associated with autoimmune disease and were 
the first genes to be identified as risk factors for autoimmunity (Rosenblum et 
al., 2015; Gough & Simmonds, 2007). These groups of highly polymorphic 
genes are also called human leucocyte antigen (HLA) or dog leucocyte antigen 
(DLA). The MHC genes consist of three classes. The class II genes have been 
associated with many human autoimmune diseases as well as with various 
canine diseases with a suggestive autoimmune aetiology, including immune-
mediated rheumatic disease (IMRD) in NSDTRs (Wilbe et al., 2009), 
hypothyroidism (Wilbe et al., 2010b; Kennedy et al., 2006b; Kennedy et al., 
2006c), and hypoadrenocorticism, also called Addison’s disease (Massey et al., 
2013; Hughes et al., 2010). The MHC class II genes can be considered common 
risk factors for autoimmunity. They code for proteins that play a crucial role in 
the adaptive immune response against foreign substances, and they are also 
important for development of tolerance against self-molecules (Abbas et al., 
2017). How genetic variations in the MHC genes contribute to development of 
autoimmune disease is not fully understood (Rosenblum et al., 2015). In dogs, 
there are three polymorphic class II genes – DRB1, DQA1, and DQB1 (Kennedy 
et al., 2001; Kennedy et al., 2000). 
By genome-wide association studies (GWAS) many more genetic loci than 
the MHC associated with complex autoimmune diseases have been identified, 
mainly in humans (Marson et al., 2015; Parkes et al., 2013), but also in dogs 
(Bianchi et al., 2015; Wilbe et al., 2010a). The majority of the associated genetic 
variants are located in non-coding regions close to or within genes and may have 
effect on gene regulation (Farh et al., 2015; Marson et al., 2015). Many of the 
candidate genes identified are preferentially expressed in immune cells and play 
a role in the development and regulation of the immune response.  
In addition to genetic factors, several environmental factors that likely 
contribute to or trigger development of autoimmune disease have been identified 
in humans, some of which, such as infections and UV-light, probably also play 
a role in canine disease (Rosenblum et al., 2015; Costenbader et al., 2012; Day, 
2008). Vaccination may also be a triggering factor in genetically susceptible 
individuals but are rare complications considering the large number of vaccines 
administrated (Toplak & Avcin, 2009; Day, 2008).  
Many of the genetic and environmental risk factors are still to be discovered, 
and little is known about how these actually interact to cause autoimmune 
diseases in dogs. Today it is difficult to estimate the risk for an individual to 
develop a complex disease, and no single genetic test can be used to predict 
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disease accurately, since multiple genetic changes contribute to disease 
development (Jostins & Barrett, 2011). Therefore, it is impossible to give 
breeding advice that applies to all autoimmune diseases and all breeds. Many 
factors have to be considered, such as the prevalence and severity of disease, and 
the size of the population. Even for a specific disease in one breed, it is often 
difficult to give any other breeding advice than not to breed from diseased 
animals.  
Identification of genetic risk factors  
Many different approaches can be undertaken to identify genetic risk factors for 
disease. In candidate gene studies, a possible association between the disease 
and one or a limited number of genes is searched for. The choices of genes may 
be based on previous studies or on the function of the gene if it suggests disease 
involvement. Genetic variation in the candidate gene is then compared between 
cases and controls, with the aim of finding genotypes or haplotypes associated 
with disease.  
The publication of the canine genome sequence (Lindblad-Toh et al., 2005), 
in combination with a rapid development in the field of genomics, has opened 
up for new ways to search the whole genome for genetic risk factors. In GWAS, 
thousands to millions of single nucleotide polymorphisms (SNPs) across the 
whole genome are analysed in cases and controls, in order to find genetic 
variants associated with disease. The first successful GWAS for a complex 
canine disease was published in 2010 (Wilbe et al., 2010a). Since then, several 
regions in the genome associated with other complex canine diseases have been 
identified (some are reviewed in: van Steenbeek et al., 2016; Lequarre et al., 
2011). Even though GWAS is a powerful methodology to find associated 
regions, these regions are large, often containing several genes. After 
identification of associated regions, other methods such as fine-mapping of the 
associated regions are necessary to narrow down the region of association, and 
targeted resequencing to identify actual genes and variants that may be involved 
in disease (Marson et al., 2015). Other methods than GWAS, such as whole 
exome and whole genome sequencing will in the future most likely help to 
identify more genetic risk factors for different diseases in dogs and humans 
(Sayyab et al., 2016; van Steenbeek et al., 2016). 
Genetic association analyses do not prove that a gene variant is causing 
disease. Functional studies focussing on the effects of genetic variation can 
provide further clues into the mechanism underlying disease (Marson et al., 
2015). One way is to study the effect that different genetic variants have on gene 
expression in different cell lines or tissues.  
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Genetic studies in dogs 
The dog population has gone through two bottleneck events during its history, 
the first when a limited number of wolfs gave rise to the domestic dog, and more 
recently during breed creation (Lindblad-Toh et al., 2005). The effect of a 
bottleneck is illustrated in Figure 1. Modern dog breeding has resulted in many 
different dog breeds with very large phenotypic variations. Although the 
diversity at species level is extensive, the genetic variation within breeds is 
relatively small, which is a consequence of bottlenecks, founder effect (a small 
number of dogs are the founders of each breed), structured inbreeding, and 
overuse of popular sires (Ostrander et al., 2017; Leroy, 2011). This breeding 
strategy has resulted in the great diversity of morphological and behavioural 
traits we see in dogs today, but it has also resulted in drawbacks. Disease causing 
mutations, which are uncommon in the general dog population, can become 
common in a breed. It is since long recognised that dogs of certain breeds are at 
high risk for some diseases. Some of these inherited disorders are related to 
conformation, while others are not related to the breed standards (Summers et 
al., 2010; Asher et al., 2009). Overall, purebred dogs have a higher prevalence 
for some disorders than crossbreds (O'Neill et al., 2014b; Bellumori et al., 2013). 
 
Figure 1. A bottleneck leads to reduced genetic diversity. 
Image: Jens Bremer   
The limited genetic diversity within dog breeds is, however, an advantage when 
performing genetic association studies. The recent breed creation has led to dogs 
having long haplotype blocks compared to humans. Haplotypes are genetic 
segments that are inherited together. As a consequence of this, fewer markers 
are needed for disease mapping in dogs compared to humans (Lindblad-Toh et 
al., 2005). Less individuals are also needed, around 100 cases and 100 controls 
often provide enough statistical power to map a complex disease in dogs 
Former 
population
New
population
 
 
23 
(Karlsson & Lindblad-Toh, 2008), in comparison to the thousands of individuals 
that are needed for similar studies in humans.  
Dogs suffer from many of the same, or similar, diseases as humans. Genetic 
association studies are technically simpler to perform in dogs than in humans, 
and diseases that are rare in humans, can be common in one dog breed. Since 
dogs live in the same environment as humans, they are exposed to some of the 
environmental factors that may influence disease onset and progression in both 
species. All of these described properties make the dog a suitable genetic model 
for human disease, and results from canine studies can be used to search for risk 
factors in human disease, in a targeted approach (Shearin & Ostrander, 2010; 
Karlsson & Lindblad-Toh, 2008). 
2.2.3 Autoantibodies  
One important characteristic of autoimmune disease is the occurrence of 
autoantibodies directed at self-molecules called self-antigens or autoantigens. 
Autoantibodies can be directly pathogenic, for example, by forming immune-
complexes that can deposit in different tissues and cause inflammation, and by 
exerting functional effects on receptors (Elkon & Casali, 2008). However, 
autoantibodies are not always pathogenic, but can be useful as markers of the 
tissue destruction and disease status. Testing for autoantibodies is an important 
diagnostic tool in the investigation of a possible autoimmune disease. 
Occurrence of autoantibodies can provide support for an autoimmune aetiology 
(Rose & Bona, 1993) and, in some instances, serve as prognostic markers 
(Scofield, 2004). Further, the presence or absence of different autoantibodies can 
be used to stratify patients into subgroups. This can be valuable in the clinical 
handling of patients, but also in research, for example in genetic studies. 
Autoantibodies to double stranded DNA (dsDNA) can serve as an example of 
an autoantibody of diagnostic and prognostic importance in human medicine. 
These autoantibodies are more specific for SLE than ANA, included as one of 
the diagnostic criteria for SLE (Tan et al., 1982) and implicated in the 
pathogenesis of lupus nephritis (Rahman & Isenberg, 2008; Koffler et al., 1967). 
Further, the autoantibody titres can correlate with disease activity and be 
predicative of disease exacerbations (Terborg et al., 1990; Swaak et al., 1986).  
Autoantibodies to dsDNA can also be present before onset of disease (Arbuckle 
et al., 2003).  
In veterinary medicine, autoantibodies have been identified in a variety of 
disorders with a suspected autoimmune aetiology, for example hypoadreno-
corticism (Boag et al., 2015), hypothyroidism (Dixon & Mooney, 1999), 
diabetes mellitus (Davison et al., 2008), and masticatory masseter myositis (Wu 
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et al., 2007; Shelton et al., 1987), but the frequency and diagnostic importance 
of these autoantibodies vary between the diseases. Routine autoantibody testing 
is only performed in a limited number of disorders, such as SLE or SLE-related 
disorders (ANA), hypothyroidism (thyroglobulin autoantibodies), and myas-
thenia gravis (acetylcholine receptor autoantibodies). While autoantibody 
analyses really have acquired a central role in the diagnosis of and research on 
human autoimmune diseases, the relevance for many of these analyses needs to 
be further explored in veterinary medicine.  
Antinuclear antibodies 
Antinuclear antibodies are a diverse group of autoantibodies directed at different 
nuclear antigens (Tan, 1989). Some autoantibodies directed at other cell 
compartments than the nucleus are also included within this group for historical 
reasons (Chan et al., 2015). Presence of high titres of ANA is a sensitive, but 
unspecific, marker for SLE in both humans and dogs (Smee et al., 2007; Monier 
et al., 1992; Bennett, 1987; Tan et al., 1982). These antibodies are also 
commonly present in other systemic rheumatic diseases (Satoh et al., 2007; 
Hansson-Hamlin et al., 2006), but they have also been reported at lower 
frequency in other canine disorders with a suspected immune-mediated 
aetiology (Dyggve et al., 2017; Bohnhorst et al., 2002; Bohnhorst et al., 2001), 
as well as in some infections such as leishmaniasis and Ehrlichia canis (Smith 
et al., 2004; Lucena et al., 1996). Healthy dogs and humans can infrequently and 
generally at low titres also have circulating ANA (Tan et al., 1997; Bennett & 
Kirkham, 1987). The prevalence of ANA in healthy individuals appears to 
increase with age in humans (Ramos-Casals et al., 2003; Tomer & Shoenfeld, 
1988) a phenomenon that has not yet been studied in dogs.  
Autoantibodies analyses 
The standard method to detect ANA in humans and dogs is by indirect 
immunofluorescence (IIF) microscopy (Bennett & Kirkham, 1987; Coons et al., 
1950). Briefly described, cells are fixed on glass slides and then incubated with 
patient sera. If autoantibodies are present in the sera, they will bind to the cell 
substrate. Different cell substrates can be used, but the human epithelial-2 (HEp-
2) cells are routinely used in human diagnostics (Chan et al., 2015) and are also 
commonly used in veterinary diagnostics (Bell et al., 1997; Hansson et al., 
1996). Fluorescent-dye conjugated secondary antibodies are then added and will 
bind to the autoantibodies (Figure 2). The slides are examined in fluorescence 
microscopy.  
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Figure 2. Principle of indirect immunofluorescence using HEp-2 as substrate 
(Di Cataldo et al., 2016), with permission.  
Two distinct IIF patterns can be identified in canine sera with HEp-2 cells as 
substrate – homogenous and speckled (Hansson et al., 1996). In the homogenous 
pattern (ANAH), the chromosomal region of mitotic cells is stained, while the 
speckled pattern (ANAS) shows negative chromosomal staining surrounded by 
positive nucleosome staining (Figure 3). These two patterns are also major ANA 
patterns in humans, but other patterns occur (Chan et al., 2015). In human 
diagnostics, different ANA patterns are associated with reactivity to different 
nuclear antigens, which can be indicative of different autoimmune disorders 
(von Mühlen & Tan, 1995). In veterinary medicine, the knowledge about the 
association between ANA patterns, the specific autoantigen reactivity, and 
clinical signs, is limited. One study reported that ANA positive dogs that display 
a homogenous ANA pattern by IIF are likely to have SLE, involving multiple 
organs, while dogs with a speckled ANA pattern more likely have SLE-related 
disease displaying primarily musculoskeletal signs (Hansson-Hamlin et al., 
2006).  
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Figure 3. Picture illustrating the two distinct immunofluorescence patterns identified in dogs with 
HEp-2 cells as substrate. Arrows pointing at mitotic cells. From paper III (Bremer et al., 2015). 
With IIF microscopy, the exact autoantibody target (the autoantigen) cannot be 
determined. To identify the autoantigen, other methods such as enzyme-linked 
immunosorbent assay (ELISA) and line blot techniques can be used. These 
methods test for specific ANA and are commonly used in human diagnostics 
(Murdjeva et al., 2011; Tozzoli et al., 2002) but not in routine veterinary 
diagnostics. Testing for specific ANA in individuals that are positive for ANA 
by IIF is a crucial step in the diagnosis of autoimmune diseases in humans, since 
different specific ANA are associated with different autoimmune disorders. 
Several specific ANA have also been identified in dogs (Hansson-Hamlin & 
Rönnelid, 2010; Welin Henriksson et al., 1998; Fournel et al., 1992; Monier et 
al., 1992; Thoren-Tolling & Ryden, 1991; Hubert et al., 1988; Monier et al., 
1988; Costa et al., 1984; Monier et al., 1980; Monier et al., 1978), but little is 
known about the clinical and pathological relevance of these specific ANA in 
dogs. The occurrence of some specific ANA that in more recent years have been 
shown to be of importance in human medicine, has not been investigated in dogs. 
Previous to the studies included in this thesis, this area of veterinary medicine 
has not received much attention in the last 10-20 years.  
Discovery of novel autoantigens 
Different approaches can lead to the discovery of novel autoantigens targeted by 
autoantibodies (Burbelo & O'Hanlon, 2014; Satoh et al., 2007). These can be 
discovered by a hypothesis driven approach, where testing for autoantibodies to 
one or a number of candidate autoantigens is performed. Other methods allow 
for a broader and more unbiased screening. One of these methods, which 
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successfully has been used in human studies to identify novel autoantigens, is 
protein arrays (Dalin et al., 2016; Landegren et al., 2016; Landegren et al., 
2015). These arrays contain thousands of full-length proteins printed on a glass 
slide, making simultaneous screening for a large number of autoantigens 
possible. The proteins are usually recombinant proteins expressed in yeast or 
insects cells, with a protein tag that enables purification and detection (Duarte & 
Blackburn, 2017).  
2.3 Immune-mediated disease in the Nova Scotia duck 
tolling retriever 
The NSDTR is a small retriever dog originating from Canada (Figure 4). The 
breed came to Sweden in 1984 (Svenska Tollarklubben, 2017a) and has since 
gained in popularity in the Scandinavian countries. By the end of 2017, 4212 
NSDTRs were registered by the Swedish Board of Agriculture, representing 
0.47% of the registered Swedish dog population (Swedish Board of Agriculture, 
2018). The Swedish NSDTR breed club is the largest of its kind in the world 
(Svenska Tollarklubben, 2017b). In comparison to many other countries, the 
breed is quite common in Sweden, making it an ideal country to study disorders 
affecting the breed. Although popular and generally considered a healthy breed 
(The Swedish Kennel Club, 2014), there have been several reports suggesting 
that dogs of this breed are at increased risk of developing immune-mediated 
disorders, in particular immune-mediated rheumatic disease (Hansson-Hamlin 
& Lilliehöök, 2009) and steroid-responsive meningitis-arteritis (Hansson-
Hamlin & Lilliehöök, 2013; Anfinsen et al., 2008; Redman, 2002). It has been 
proposed that the high incidence of immune-mediated disease observed in this 
breed is due to bottle necks caused by two canine distemper outbreaks in Canada 
in the beginning of the 20th century. Hypothetically, dogs that survived and 
repopulated the breed had particularly reactive or strong immune systems 
allowing them to survive, but now making their offsprings prone to develop 
immune-mediated disease (Hughes et al., 2010; Wilbe et al., 2010a). In 2002, 
Hansson-Hamlin, initiated the “Toller Project” and started collecting clinical 
data and blood samples from NSDTRs with immune-mediated disease. The aim 
was to clinically characterize and identify biomarkers and genetic risk factors 
for these diseases in NSDTRs.    
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Figure 4. A Nova Scotia duck tolling retriever.  
Photo: Jens Bremer  
2.3.1 Immune-mediated rheumatic disease  
The clinical features of immune-mediated rheumatic disease (IMRD) in 
NSDTRs was described in 2009 by Hansson-Hamlin and Lilliehöök. The disease 
most often affects middle-aged dogs and is characterised by chronic stiffness, 
mainly after rest, and pain from multiple joints, indicative of non-erosive 
polyarthritis. Affected dogs sometimes show other clinical signs such as muscle 
pain, skin problems, and fever. A majority of cases are positive for ANA by IIF. 
Improvement of clinical signs can often be obtained with glucocorticoid 
treatment. The occurrence of autoantibodies, response to immunosuppressive 
treatment, and genetic association to the MHC class II genes, suggest that IMRD 
is an autoimmune disease (Hansson-Hamlin & Lilliehöök, 2009; Wilbe et al., 
2009). The clinical and diagnostic findings of IMRD are overlapping with SLE, 
and some other systemic rheumatic diseases, and it can therefore be referred to 
as an SLE-related or SLE-like disease.  
2.3.2 Steroid-responsive meningitis-arteritis  
Steroid-responsive meningitis-arteritis (SRMA) has been reported in several dog 
breeds including NSDTRs (Hansson-Hamlin & Lilliehöök, 2013; Tipold & 
Schatzberg, 2010; Tipold & Jaggy, 1994). It is a disease primarily affecting 
young dogs. The typical acute form is characterized by fever, lethargy, intense 
neck pain and stiffness, as well as general signs of inflammation, such as 
increased number of white blood cells and increased concentrations of acute-
phase proteins in sera. Analysis of cerebrospinal fluid reveals presence of 
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inflammatory cells but absence of identifiable infectious organisms (Lowrie et 
al., 2009). Increased concentrations of immunoglobulin A in serum and 
cerebrospinal fluid can sometimes also be detected (Maiolini et al., 2012; Lowrie 
et al., 2009). As the name implies, the clinical signs of the condition respond to 
glucocorticoids (which is a steroid). Improvement of clinical signs is normally 
rapid after treatment has been initiated, but recurrence of signs is common 
(Biedermann et al., 2016; Hansson-Hamlin & Lilliehöök, 2013; Lowrie et al., 
2009). Antinuclear antibodies are not detected in NSDTRs with SRMA 
(Hansson-Hamlin & Lilliehöök, 2013). Although the immune system is likely to 
be involved in the pathogenesis, the exact cause of disease is unknown (Tipold 
& Schatzberg, 2010). It is not clear if SMRA is a primary autoimmune disease 
or a secondary autoimmune reaction to unknown stimuli.  
2.3.3 Epidemiology 
Previous studies of immune-mediated diseases in NSDTRs are mainly case-
reports or case-control studies (Hansson-Hamlin & Lilliehöök, 2013; Wilbe et 
al., 2010a; Hansson-Hamlin & Lilliehöök, 2009; Wilbe et al., 2009). Such 
studies are important in highlighting a problem in a breed but do not give 
information about disease frequency. To measure the disease frequency, 
information about the population at risk is necessary, information that can be 
difficult to obtain. However, in a previously published study, disease frequency 
was estimated in a limited number of Norwegian NSDTRs. The study identified 
nine dogs that were, or had been affected, by SRMA, resulting in a prevalence 
of 2.5% (Anfinsen et al., 2008). To compare, the prevalence of SRMA has been 
estimated in UK dogs of many different breeds to be 0.15% (Wiles et al., 2017). 
Although several studies suggest that NSDTRs are at increased risk of immune-
mediated diseases, no previous studies have been able to show that such is the 
case. To show that dogs of a specific breed are at increased risk, a comparison 
of the disease frequency in the breed of interest to other dog breeds is necessary.  
2.3.4 Genetics 
Early observations in NSDTRs suggested that IMRD and SRMA are genetic 
disorders, but observations did not support monogenic inheritance, instead 
complex inheritance patterns were suspected (Hansson-Hamlin & Lilliehöök, 
2009; Wilbe et al., 2009; Anfinsen et al., 2008). By a candidate driven approach, 
Wilbe et al. (2009) showed that IMRD are associated with a particular MHC 
class II haplotype, and also that general homozygosity in the MHC class II region 
increased the risk of IMRD. No association between SRMA and MHC class II 
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was found. In 2010, IMRD and SRMA were the first complex canine disorders 
to be successfully mapped by a GWAS (Wilbe et al., 2010a). Five candidate 
loci, located on chromosomes 3, 8, 11, 24, and 32 were identified. The loci on 
chromosome 3, 8, 11, and 24 were associated with IMRD and the locus on 
chromosome 32 showed association to both IMRD and SRMA. All of the 
identified regions contain strong candidate genes for follow-up studies. 
Interestingly, several of the candidate genes are involved in the nuclear factor of 
activated T-cells (NFAT) pathway. The NFAT family is a group of transcription 
factors important for T-cell activation and regulation, and is also important for 
the function of many other immune cells (Muller & Rao, 2010).  
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The major aim of this study was to increase the knowledge of disease frequency, 
genetic risk factors, and occurrence of autoantibodies in dogs with immune-
mediated disease, specifically, in dogs of the breed NSDTR.  
 
The specific aims were to:  
 
Ø investigate the overall incidence of disease and describe the general 
disease pattern in NSDTRs,  
Ø determine the incidence of immune-mediated disease in general, and that 
of IMRD and SRMA in particular, and, to test the hypothesis that 
NSDTRs are predisposed to these disorders,  
Ø perform resequencing of genetic loci previously identified as associated 
with IMRD and SRMA in NSDTRs in order to identify risk genotypes 
and haplotypes, then evaluate how these are associated with expression of 
candidate genes, 
Ø investigate if particular sub-phenotypes of IMRD based on ANA pattern 
(ANAH and ANAS) are associated with different genetic variants,  
Ø identify both new and known canine autoantibodies with several different 
methods, and  
Ø investigate if different ANA patterns (ANAH and ANAS) are associated 
with different autoantibodies.  
  
3 Aims  
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Detailed methods are described in the respective papers. Following are some 
comments on the materials and one the most important methods.  
4.1 Study populations 
Study I was a retrospective cohort including dogs insured by Agria Pet 
Insurance. The study population included all dogs insured before one year of age 
during the years 1995 to 2006 and consisted of 445,336 dogs of which 2,890 
were NSDTRs.  
The studies II-IV were retrospective case-control studies including privately 
owned dogs, with confirmed (NSDTRs only) or suspected immune-mediated 
disease (dogs of other breeds than NSDTRs), and healthy control dogs. Study 
IV also included human patients and controls. Samples from NSDTRs had been 
collected during the years 2002 and 2016 to be included in different research 
studies as part of the “Toller Project”. Sampling was coordinated by Hansson-
Hamlin, and performed by researchers involved in the studies, or by different 
veterinarians throughout the country. Some Finnish dogs were also included in 
study II.  
Patients with IMRD displayed musculoskeletal signs with shifting lameness, 
stiffness, and pain from multiple joints upon manipulation. Clinical signs had 
been apparent for at least 14 days before inclusion and no other cause of the 
clinical signs was suspected. Dogs affected with IMRD were tested for ANA 
with IIF, and ANA-positive dogs were divided into two groups, depending on 
the type of ANA pattern, ANAS and ANAH. Dogs with SRMA had typical 
clinical signs of SRMA and showed resolution of clinical signs after 
glucocorticoid treatment. Analysis of cerebrospinal fluid was performed in some 
cases.   
4 Comments on materials and methods 
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4.2 Measuring disease frequency (paper I) 
Disease frequencies were assessed using data on number of veterinary visits 
registered by the Agria Pet Insurance’s database. This database has been 
validated for epidemiological studies and is described in detail elsewhere 
(Egenvall et al., 1998). Following is a brief description of the database. If the 
cost for a veterinary visit exceeds the deductible limit, the main cause of the 
veterinary visit is registered as a diagnostic code in the database. The diagnostic 
code is assigned by the attending veterinarian from a standard registry.  
Unfortunately, the standard registry is not perfect or complete, specific codes 
for some disorders, including IMRD and SRMA are lacking. To overcome this 
problem, we selected other diagnostic codes that were likely to represent these 
disorders. To describe the general disease pattern in NSDTRs, diagnostic codes 
were grouped into different categories based on organ systems and disease 
processes. Incidence rates were calculated by taking the number of veterinary 
visits, divided by the time at risk. The rates were multiplied by 10,000 and 
presented as number of cases per 10,000 dog years at risk (DYAR). If a dog had 
more than one claim for the investigated disease or disease category, only the 
first claim was counted. Incidence rates for NSDTRs were compared with 
incidence rates for other dog breeds, to estimate the incidence rate ratio/relative 
risk (RR). Two groups were established for comparison, the first consisting of 
all dogs except NSDTRs, the other of all retrievers except NSDTRs. These were 
then compared to the NSDTRs. 
4.3 Genetic studies (paper II) 
4.3.1 Sequencing and analysis of MHC class II 
The polymorphic exon 2 of MHC class II was sequenced for each of the DRB1, 
DQA1, and DQB1 genes in ANA-positive IMRD cases and healthy control dogs. 
Cases were subdivided based on ANA pattern as ANAS or ANAH (six cases were 
not possible to classify due to lack of sera). Sequences were analysed and 
haplotypes and genotypes were assigned to each dog. The total number of cases 
and controls carrying a specific allele or genotype was compared with cases and 
controls not carrying it, using a 2x2 contingency table. The total number of 
homozygous dogs was also compared in cases and controls. Odds-ratios (OR) 
and p-values (Yates’ chi-square test) were calculated for each allele, haplotype 
and genotype.  
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4.3.2 Re-sequencing of associated loci, SNP selection, and genotyping                             
To identify candidate variants associated with IMRD and/or SRMA, the five 
regions on chromosome 3, 8, 11, 24, and 32 that were previously found to be 
associated with IMRD and SRMA (Wilbe et al., 2010a) were re-sequenced in 
four IMRD cases, two SRMA cases, and three healthy control dogs using 
NimbleGen capture and Illumina sequencing. The data was analysed with 
various tools to discover variants (SNPs, indels, and structural changes) in the 
genomic sequence between IMRD, SRMA, and healthy controls. From this re-
sequencing data, 308 SNPs from the five loci were chosen for genotyping in all 
the available cases and controls. The SNPs were selected based on the following 
criteria: difference in allele frequency between cases and controls, positioned in 
either protein coding region, 5’ UTR or 3’ UTR, and located within non-coding 
conserved elements. The 308 SNPs were genotyped by GoldenGate Genotyping 
Assay. Association analyses were performed using PLINK (Purcell et al., 2007). 
Healthy controls were compared with each of the different groups: SRMA cases, 
all IMRD cases, and the two subgroups; IMRD ANAS and IMRD ANAH. 
Conditional analyses were also performed where ANAS dogs homozygous for 
the MHC class II risk haplotype, ANAH dogs homozygous for MHC class II, and 
ANAH dogs with the identified risk allele were included respectively. The SNPs 
that showed the highest association to disease were selected for investigation of 
its effect on gene expression.  
4.3.3 Expression studies 
Peripheral blood from 167 healthy NSDTRs were collected for gene expression 
studies of the candidate genes. Genomic DNA and RNA were extracted from the 
samples and genotyping of 51 SNPs was performed with either pyrosequencing 
or Sanger sequencing. Gene expression was measured by real-time PCR and 
normalised to the reference gene TBP. Gene expression levels were then 
correlated with genotype and haplotypes using one-way ANOVA.  
4.4 Autoantibody investigations 
4.4.1 Indirect immunofluorescence (paper II-IV) 
Canine sera were tested for ANA by IIF microscopy as previously described 
(Hansson et al., 1996). Analyses were performed by the staff at the Clinical 
Pathology Laboratory, University Animal Hospital, SLU, or at Euroimmun, 
Lübeck, Germany. Monolayers of HEp-2 cells were used as substrate. The glass 
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slides were examined by fluorescence microscopy and considered positive at a 
titre of ³1:100. The visible nuclear pattern (ANAH or ANAS) was registered for 
each dog positive for ANA.  
4.4.2 Enzyme-linked immunosorbent assay and line immunoassay 
(paper III) 
We screened canine sera for reactivity to 18 antigens known to be associated 
with autoimmune disease in humans. Four different enzyme-linked 
immunosorbent assays (ELISA) and a line immunoassay (Euroline ANA profile 
5), originally developed for detection of human ANA, were used. The analyses 
were performed at Euroimmun by automated systems according to the 
manufacturer’s instructions, with the exception of the secondary anti-human 
antibody that was exchanged for an anti-dog antibody. We used the highest 
observed value obtained from a serum in the healthy group as a cut-off value and 
compared the difference in positive cases between ANAH and ANAS groups with 
Fisher exact probability test (two tailed).  
4.4.3 Protein array screen (paper IV) 
The HuProtTM Human Proteome Microarray v2 (CDI Laboratories) was used to 
search for novel autoantibodies. The arrays contain approximately 17,000 
proteins printed on a glass slide. We modified the human protocol to work with 
canine sera. Briefly described, the arrays were incubated with 1:200 diluted 
canine sera from 12 IMRD patients and nine healthy controls, followed by 
incubation with a fluorophore conjugated anti-dog antibody. The arrays were 
scanned using a microarray scanner. To search for increased autoantibody 
signals in IMRD patients, we used a cut-off of mean + 3SD (log-transformed 
data) based on the healthy controls.  
4.4.4 Radio-ligand binding assay (paper IV) 
To validate our findings from the protein array screen, and to screen more dogs 
for autoantibodies to the candidate autoantigens, we used radio-ligand binding 
assays. Recombinant proteins were expressed in vitro in the presence of 35S-
labeled methionine and immunoprecipitated with canine patient and control sera. 
Serum antibodies were immobilised to protein A Sepharose and radioactivity 
was measured in a microbeta counter. Autoantibody index was calculated as 
((sample value mean-negative control)/(positive control-negative control))x100. 
Cut-off values were calculated from healthy controls as mean+5SD (mean+7SD 
for the RBMX antigen).  
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5.1 Disease frequency in Nova Scotia duck tolling 
retrievers (paper I) 
5.1.1 Overall disease frequencies  
Of the 2890 NSDTRs included in the study, 51% had at least one veterinary visit 
during the study period. The incidence rate for veterinary visits was 1300 cases 
per 10,000 DYAR, somewhat higher (RR 1.1, p=0.0075) compared to all other 
breeds combined, but similar to other retrievers (RR 0.96, p=0.091). The most 
common causes of veterinary visits in NSDTRs were injuries, gastrointestinal 
disease, and locomotor disorders.  
5.1.2 Frequencies and relative risk of immune-mediated disease 
The overall incidence rate for immune-mediated (named immunological in paper 
I) disorders was 44 cases per 10,000 DYAR, approximately the same as in other 
breeds and other retrievers. Immune-mediated disorders did not belong to one of 
the most common causes of veterinary visits in NSDTRs. Immunological 
disorders consisted of three subgroups of disorders; allergic, autoimmune, and 
various (other immune-mediated disorders not possible to classify as allergic or 
autoimmune, e.g. the diagnosis “immunological changes whole animal”). Auto-
immune disorders, and disorders belonging to the group “various immunological 
disorders”, were significantly more common in NSDTRs than in other breeds 
(RR 2.7, p=0.00025 and RR 3.9, p=0.00011, respectively). The incidence for 
neurological disorders (not belonging to the group immune-mediated disease) 
was also higher in NSDTRs than in other breeds (RR 1.7, p<0.0001), in 
particular neurological infections/inflammations (RR 9.0, p<0.0001). 
5 Results 
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The incidence rate for disorders representing IMRD was estimated to 6.8 
cases per 10,000 DYAR in NSDTRs, 18 times higher than in other breeds and 
30 times higher than in other retrievers. For SRMA, the incidence rate was 20 
cases per 10,000 DYAR, 12 times higher than in other breeds.   
5.2 Genetic studies in Nova Scotia duck tolling retrievers 
(paper II) 
5.2.1 Association of the MHC class II genes with IMRD 
By sequencing 122 dogs for MHC class II polymorphism, five different 
haplotypes, forming 10 genotypes were identified. Haplotype 2 (DRB1*00601/ 
DQA1*005011/DQB1*02001) was strongly associated with IMRD ANAS 
(OR=9.7 and p<0.0001 compared with controls), with an even higher OR in 
homozygote individuals (genotype 2, OR=21 and p<0.0001). No association was 
found at the haplotype or genotype level for ANAH, but at the allelic level a 
significant association was identified for DQA1*00601 (OR=5.1, p=0.00017). A 
general homozygosity regardless of haplotype was also associated with ANAH 
(OR=5.1 and p=0.0016 including all genotypes).  
5.2.2 Additional genes associated with IMRD and SRMA 
Resequencing of the other five genetic risk loci discovered by GWAS (Wilbe et 
al., 2010a) identified 426 SNPs and 88 indels with a potential functional effect. 
Of these, 308 SNPs following the risk haplotype patterns, were genotyped in the 
entire sample set to identify risk variants associated with SRMA and ANA 
positive IMRD, including the two sub-phenotypes ANAH and ANAS. The five 
different loci showed association to different, but also overlapping, phenotypes. 
For example, the strongest association on Chr 11 was with all IMRD cases, while 
the risk locus on Chr 32 showed two independent signals, one to SRMA and one 
to ANAS. The SNPs that showed the highest association to disease were chosen 
to study their effect on gene expression. Functional changes associated with the 
risk haplotypes were identified in 11 genes located on the five chromosomes. 
Significant changes in gene expression were identified for 10 genes. In addition, 
a non-synonymous SNP in HOMER2 was associated with the IMRD ANAH risk 
haplotype. A non-significant trend towards lower mRNA expression levels of 
this gene was also observed in the risk haplotype. The results are summarized in 
Table 1.  
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Table 1. Genes associated with IMRD and SRMA phenotypes. The strongest association to a phenotype marked with bold “+”, regular “+” means the gene is 
associated with a particular phenotype. Modified from paper II (Wilbe et al., 2015). 
chromosome SNP ID gene/phenotype gene effect all ANA ANAS ANAS+DLA ANAH ANAH+DLA SRMA 
11 11:67537177 PTPN3 down + + + + + - 
24 24:36087012 WFDC3 up + - - + + - 
32 32:24542001 BANK1 up + + + - + - 
 32:24827518 DAPP1 up - - - - - + 
 32:24827518 LAMTOR3 up - - - - - + 
 32:24827518 DDIT4L up - - - - - + 
 32:24827518 PPP3CA up - - - - - + 
3 3:57484486 AP3B2 up + + - - - + 
 3:57432981 WHAMM up + + - + + - 
 3:57546568 HOMER2 
nsSNP 
(Thr->Ala)1 
+ - - + + - 
8 8:68708503 VRK12 up + - - + + - 
1. We observed also a trend towards down-regulation of HOMER2 in the risk haplotype, although it did not reach statistical significance due to small sample size. 
2.  The strong genetic association signal with SRMA on chromosome 8 was not associated with VRK1 expression levels. 
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While some of the genes showed association to only one phenotype, others were 
shared between IMRD ANAH and IMRD ANAS phenotypes. There was little 
overlap between the genes associated with IMRD and SRMA, but one gene, 
AP3B2, was associated with both IMRD ANAS and SRMA (Figure 5). 
  
 Figure 5.Venn diagram showing overlap between clinicopathological  
features and associated genes. From paper II (Wilbe et al., 2015). 
5.3 Autoantibodies in dogs 
5.3.1 Specific antinuclear antibodies and ANA pattern (paper III) 
Sera from 240 dogs with suspicion of autoimmune disease and sera from 27 
healthy control dogs were screened for specific ANA. Of the 240 sera, 210 had 
been selected because they were ANA positive and 30 were ANA negative. Of 
the 210 ANA positive samples, 141 (67%) samples were classified as ANAS and 
68 (32%) as ANAH (one sample was not possible to classify and excluded from 
further analyses). The patient sera, as well as sera from 27 healthy control dogs, 
were evaluated and compared with regards to specific ANA reactivity. Dogs in 
the ANAH group, frequently had high levels of dsDNA and nucleosome 
autoantibodies, detected by ELISA and the line immunoassay. Because previous 
investigations had yielded inconclusive results about dsDNA autoantibodies in 
dogs, these results were validated with Crithidia luciliae indirect 
immunofluorescence test (CLIFT), a method with high specificity for detecting 
dsDNA autoantibodies in humans. With CLIFT, dsDNA autoantibodies were 
confirmed in 10 out of the 39 samples that were positive in the ELISA and/or 
line immunoassay. Dogs in the ANAS group, frequently had high levels of 
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autoantibodies to ribonucleoproteins (RNP) and to Smith antigen (Sm). In 
individual dogs, we also found autoantibodies to SS-A, SS-B, Jo-1, Scl-70, and 
PCNA. In conclusion, we found that the types of ANA pattern are associated 
with reactivity to particular nuclear antigens.  
5.3.2 Identification of interleukin enhancer-binding factors 2 and 3 as 
canine autoantigens (paper IV) 
By a protein array screen, we identified interleukin enhancer-binding factor 2 
(ILF2) as a potential autoantigen in IMRD patients. Autoantibodies to ILF2 were 
identified in seven of 12 IMRD patients, but only in patients with ANAS. To 
confirm the results from the protein array screen that ILF2 is a common 
autoantigen in IMRD ANAS patients, we performed a radio-ligand binding assay 
on the same sera as well as on sera form a larger cohort. Sera from a total of 29 
IMRD ANAS patients and 121 dogs from other breeds with ANAS were 
screened. Autoantibodies to ILF2 were present in 27/29 (93%) of sera from 
IMRD ANAS patients and in 49/121 (40%) sera from ANAS dogs of other breeds 
than NSDTRs (Figure 6). The ILF2 autoantibodies were only present in ANAS 
sera. We observed a strong breed difference regarding ILF2 autoantibodies. 
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Figure 6. Radio-ligand binding assay was used to validate ILF2 as an autoantigen  
in the discovery and in an extended cohort. From paper IV (Bremer et al., 2018). 
The ILF2 protein is expressed as a heterodimeric complex with the protein 
interleukin enhancer-binding factor 3 (ILF3). Because of this functional 
interaction between ILF2 and ILF3, and because ILF2 autoantibodies have been 
reported to occur together with ILF3 autoantibodies in mice and humans 
(Kuroda et al., 2006; Satoh et al., 1999), we screened the canine samples for 
ILF3 autoantibodies. A majority (87%) of the samples that were ILF2-positive 
were also ILF3-positive. Cross-reactivity studies showed that this was not due 
to cross-reactivity. We also identified ILF2 and ILF3 autoantibodies in five 
human patients with either SLE or Sjögren’s syndrome.  
The sera were also tested for autoantibodies to RNA-binding motif protein, 
X chromosome, RBMX (also known as hnRNP G), previously described as an 
autoantigen in dogs. These autoantibodies were only detected in 19 of 119 (16%) 
sera from ANAS dogs and were only present in German shepherd dogs, cross-
breeds, and in one dog of unknown breed.  
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The work presented in this thesis builds on previous studies of immune-mediated 
diseases in NSDTRs (Hansson-Hamlin & Lilliehöök, 2013; Wilbe et al., 2010a; 
Hansson-Hamlin & Lilliehöök, 2009; Wilbe et al., 2009). The original idea was 
to focus only on this breed, but the investigations were extended to include dogs 
of other breeds (paper III and IV) and also humans (paper IV). Although this 
work focuses on studies of immune-mediated diseases in NSDTRs, it also 
provides information relevant to the larger research fields of autoimmune 
diseases in dogs and humans.  
6.1 Nova Scotia duck tolling retrievers are predisposed 
to autoimmune diseases 
As hypothesised, and as suggested but not actually shown by others (Hansson-
Hamlin & Lilliehöök, 2013; Hansson-Hamlin & Lilliehöök, 2009; Anfinsen et 
al., 2008; Redman, 2002), NSDTRs were here shown to be predisposed to 
autoimmune disorders, particularly to IMRD and SRMA (paper I). Information 
about which disorders are high-risk in a breed can be of value to veterinarians, 
dog breeders and owners, and researchers. Based only on the results from paper 
I, it is not possible to draw conclusions about the causes of the identified 
predispositions in NSDTRs. A breed predisposition can reflect a genetic 
component, but can in some cases be explained by lifestyle factors or owners’ 
attitude to seek veterinary care. It should be noted that NSDTRs were compared 
to all other dog breeds combined, and to all other retrievers combined, but not to 
every single breed separately. Individual breeds might have similar, or higher, 
incidence rates for autoimmune disease, as NSDTRs. Considered together with 
results from previous studies, showing that genetic factors contribute to IMRD 
and SRMA (Wilbe et al., 2010a; Wilbe et al., 2009), it is strongly indicated that 
6 Discussion and future perspectives  
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the high relative risk observed for these two disorders reflect a genetic 
predisposition in NSDTRs.  
The incidence rates for IMRD and SRMA were >10 times higher in NSDTRs 
than in other dog breeds combined. Even so, they were lower than for several 
other conditions. Overall, morbidity in NSDTRs was slightly higher compared 
to all other breeds but similar to retrievers from other breeds. One of the purposes 
of describing the whole disease pattern in NSDTRs was to rank disorders in 
terms of how common they are. This information is helpful, because it is 
sometimes difficult to interpret incidence for a disease, unless it is done in 
comparison to incidences of other diseases. The information about relative risk 
and incidence should be considered together, because preventive measures 
ideally should be directed at disorders that are common, severe, and high-risk. 
Although being one of the primary aims with paper I, it turned out to be difficult 
to estimate exact incidence rates for IMRD and SRMA, mainly because of the 
problem with diagnostic classification. A review of diagnostic codes assigned to 
the NSDTRs included as IMRD cases in the case-control studies (paper II and 
IV), showed that these dogs often receive the diagnostic code lameness. 
Lameness was not included in the IMRD category, because it represents a large 
number of different disorders. The incidence rates for IMRD and SRMA in paper 
I are therefore likely underestimates of true incidence, and insurance data might 
not actually be the best way to assess disease frequency for these diseases. Other 
attempts have been made to estimate the disease frequency of IMRD and SRMA 
in NSDTRs, by owner questionnaires, but these unpublished studies suffer from 
other drawbacks such as lack of validation, participation bias, and an ill-defined 
population at risk.  
The overall disease description in NSDTRs presented in paper I provides 
novel information that should be of interest to different stakeholders. The study 
is based on insurance data, which benefits from containing information about 
both the disease events, and the background population (O'Neill et al., 2014a; 
Egenvall et al., 2009). A recent report in Sweden stated that approximately 9 of 
10 dogs are insured (Agria Pet Insurance, 2017; Novus, 2017). An estimated 
40% of these dogs are insured by Agria Pet Insurance (Agria Pet Insurance, 
personal communication, 2018). Thus, the dogs insured by Agria represent a 
large proportion of the entire Swedish dog population, and the insurance 
database contains data from sufficient number of dogs to provide power to gain 
significant results. One of the major drawbacks with insurance data concerns the 
problem of diagnostic accuracy. The Agria Pet Insurance database has been 
validated, and the agreement between the database and medical record was 
considered fair (Egenvall et al., 1998) but it can be assumed to vary between 
different diagnoses. Another problem is lack of diagnostic codes for some 
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disorders. A new, hopefully improved, diagnostic registry has recently been 
released, which might solve some of these issues (Svensk Djursjukvård, 2017).   
6.2 IMRD and SRMA are associated with different but 
overlapping sets of genes 
It was previously shown that MHC class II genes are strong genetic risk factors 
for IMRD but not SRMA (Wilbe et al., 2009). In addition to the MHC, five 
genetic loci associated with either IMRD or SRMA had been identified (Wilbe 
et al., 2010a). Paper II builds on these previous findings. A more detailed 
analysis of the associated loci than what was previously done was performed. 
Unlike the previous studies, only ANA-positive IMRD cases were included. The 
IMRD cases were further subdivided into two sub-phenotypes, based on the 
ANA pattern, in order to identify potential risk factors associated with different 
sub-phenotypes. In paper II, it is shown that the haplotype 2 
(DRB1*00601/DQA1*005011/DQB1*02001), which was previously found to 
be strongly associated with IMRD, is only associated with IMRD ANAS and not 
with IMRD ANAH. A similar haplotype (DRB1*00601/DQA1*005011/DQB1* 
00701) has been associated with other canine disorders, including immune-
mediated haemolytic anaemia in multiple breeds (Kennedy et al., 2006a) and 
chronic hepatitis in English Springer Spaniels (Bexfield et al., 2012). No MHC 
class II haplotypes or genotypes were found to be significantly associated with 
IMRD ANAH, which might be due to lack of power. A general homozygosity in 
MHC class II region was, however, significantly associated with IMRD ANAH.   
The other genetic regions showed a complex pattern of association where 
some regions showed association to more than one disease or sub-phenotype. In 
order to identify functional changes associated with disease, expression studies 
of the genes in the associated regions were performed in blood from healthy 
NSDTRs. Gene expression between dogs with risk and non-risk haplotypes were 
compared. Eleven genes showed altered expression associated with one or more 
of the risk haplotypes (Table 1 and Figure 5). The SRMA risk haplotypes were 
associated with altered expression of one gene on chromosome 3 (AP3B2) and 
four genes on chromosome 32 (DAPP1, LAMTOR3, DDIT4L, and PPP3CA). 
Altered expression of AP3B2 was also associated with IMRD ANAS risk. Three 
genes (PTPN3, WHAMM, and BANK1) showed altered expression in both IMRD 
ANAH and IMRD ANAS risk haplotypes and three genes (WFDC3, HOMER2, 
and VRK1) showed association to only IMRD ANAH. The altered gene 
expression in HOMER did not reach statistical significance but a non-
synonymous SNP in this gene was associated with the risk. Some of the 
identified genes are well-studied and have been associated with various human 
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autoimmune diseases, such as BANK1 (Muhali et al., 2013; Rueda et al., 2010; 
Kozyrev et al., 2008). Other genes not previously described in autoimmunity 
provide good candidates for follow-up studies.  
To identify the genetic variants causing altered gene expression further 
functional studies are necessary, since the identified SNPs are not necessarily 
functional, but rather in linkage disequilibrium with the functional SNP. One 
way to do this is by using transient transfection in different cell lines with 
reporters carrying either the risk or non-risk SNP. The effect of potentially 
disease-causing coding SNPs could be studied by cell culture methods 
overexpressing the genes containing the mutations.   
The results from study II throw light on the genetic complexity of immune-
mediated disease in dogs. Variations in multiple genes contribute to disease, 
where some gene variants are shared between diseases and sub-phenotypes, 
while others appear to be specific for only one phenotype. In addition to the risk 
factors identified in paper II, there are probably unidentified genetic, epigenetic, 
and environmental risk factors that contribute to development of IMRD and 
SRMA in NSDTRs. Furthermore, a future challenge will be to establish how 
these risk factors functionally interact to cause disease. Modern methods such as 
whole genome and transcriptome sequencing of affected dogs, could potentially 
provide further clues into the genetics underlying IMRD and SRMA. Although 
our understanding of how genetic factors contribute to the development of these 
diseases have increased greatly since they were first noticed in NSDTRs, a lot is 
still to be learned and understood. A future priority is to determine which 
combination of genetic risk factors that give the highest risk of developing 
IMRD and SRMA. To do this, recruitment of more diseased dogs would be 
needed to provide enough power to gain statistically significant results.  
6.3 Several autoantigens identified in ANA-positive dogs  
Paper III and IV aimed at finding autoantibody targets in ANA-positive IMRD 
NSDTRs and also in dogs of other breeds. Several different methods, originally 
developed for detection of human autoantibodies, were adapted to work with 
canine sera. The frequencies of different ANA patterns were described and the 
speckled pattern was the common pattern, in agreement with earlier studies 
(Hansson-Hamlin et al., 2006; Hansson et al., 1996). Similarly to what is already 
well established in humans (Chan et al., 2015), different ANA patterns were 
found to be associated with reactivity to different autoantigens. Results from 
previous studies already suggested that this was the case (Hansson-Hamlin & 
Rönnelid, 2010; Welin Henriksson et al., 1998; Fournel et al., 1992; Monier et 
al., 1992; Monier et al., 1988; Monier et al., 1980) but it has not been shown as 
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clearly before. In most of the older studies, different substrates, such as rat liver 
or mouse blood smears, were used for ANA detection. With these substrates, the 
type of pattern can be difficult to determine and false positive results might be a 
problem (Hansson et al., 1996). They have therefore largely been replaced by 
HEp-2 cells.  
In paper III nucleosomes and dsDNA were found to be common autoantibody 
targets in ANAH sera, and RNP/Sm to be targets in many ANAS sera, in 
agreement with findings in humans (Chan et al., 2015). In humans, dsDNA and 
Sm autoantibodies show high specificity for SLE (Petri et al., 2012; Satoh et al., 
2007; Tan et al., 1982). RNP autoantibodies are associated with mixed 
connective tissue disease (Sharp et al., 1972) but might also occur in other 
systemic rheumatic diseases. Both RNP and Sm autoantibodies have previously 
been described in dogs (Hansson-Hamlin & Rönnelid, 2010; Welin Henriksson 
et al., 1998; Fournel et al., 1992; Hubert et al., 1988; Costa et al., 1984) but it is 
difficult to compare the frequency of positive cases between our present study 
and previous studies, mainly because the inclusion criteria and methods of 
autoantibody detection differ. Previous studies of dsDNA autoantibodies in dogs 
have yielded inconclusive results (Monestier et al., 1995; Fournel et al., 1992; 
Monier et al., 1992). In a portion of the dogs these findings were validated with 
CLIFT, a highly specific method for dsDNA autoantibody detection in humans 
(Enocsson et al., 2015; Haugbro et al., 2004), supporting the conclusion that 
dsDNA autoantibodies exist in dogs.    
One of the major limitations of study III was that a large representative 
control group was lacking. This led to difficulties establishing proper cut-off 
values. Still, many of the positive samples showed high reactivity, well above 
cut-off. In a number of ANA-positive dogs, mainly in the ANAS group, the 
autoantigen could not be identified by the targeted approach used in paper III. A 
screening of a large number of sera from NSDTRs with the same methods 
described in paper III (unpublished data), revealed negative results for known 
autoantibodies in the majority of ANAS sera from IMRD patients. This led us to 
study IV, where a broad screening of autoantibodies in IMRD patients with focus 
on the ANAS group was performed. The chances of finding the autoantigens 
using protein arrays with recombinant human proteins were fair, since it was 
known that these patients have autoantibodies that cross-react with human 
proteins (HEp-2 cells) and that autoantibodies are often directed at conserved 
proteins (Utz et al., 2000). Although there are limitations with this technology 
that can lead to false negative results (Duarte & Blackburn, 2017), a good 
candidate autoantigen, ILF2, was found, and was further validated as a canine 
autoantigen with an independent method in a larger cohort of dogs. Indeed, the 
prevalence of autoantibodies directed against ILF2, and the associated protein 
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ILF3, was very high in ANAS sera from several dog breeds, including NSDTRs. 
Autoantibodies to RBMX, previously described as an important autoantigen in 
dogs with ANAS (Soulard et al., 1993; Soulard et al., 1991), were found at a 
lower frequency. A clear breed difference in autoantibody reactivity was 
observed which indicates, and also supports by the findings in study II, that the 
genetic background is important for the autoantibody development. The ILF2, 
ILF3, and RBMX proteins belong to the same complex, but autoantibodies to 
RBMX were found only in German shepherd dogs, mixed breeds, and in one 
dog of unknown breed, while ILF2/ILF3 autoantibodies were found in NSDTRs, 
cocker spaniels, and other dogs breeds. ILF2 and ILF3 are expressed in many 
tissues where they function as transcription factors crucial for expression of for 
example interleukin-2 and interleukin-13 (Kiesler et al., 2010; Shi et al., 2007; 
Zhao et al., 2005; Corthesy & Kao, 1994; Kao et al., 1994). Why tolerance is 
lost against these proteins is unknown but intriguing.  
Preliminary analyses of combined data from paper III and IV, together with 
some additional unpublished data, show that in almost all ANA-positive dogs, a 
specific reactivity can be identified. Autoantibodies to nucleosomes/dsDNA are 
found in most ANAH sera, and autoantibodies to either ILF2/ILF3, RBMX, or 
RNP/Sm can be found in almost all ANAS sera. It is possible, that testing for 
these autoantibodies can replace, or be an additional test to, the conventional 
ANA test. The conventional ANA test is laborious and somewhat subjective 
since it is manually interpreted (Satoh et al., 2007), and other methods may be 
more suitable for large scale testing. However, more work is required to 
elucidate if these autoantibodies have a role as diagnostic markers. As discussed 
earlier, testing for specific ANA is important in the diagnosis of human systemic 
autoimmune disease, but investigation of autoantibodies in canine systemic 
autoimmune disease is mainly restricted to the IIF-ANA test. More specific test 
in dogs could be an aid in the diagnosis, and potentially help in monitoring of 
patients. To study the potential clinical use of the autoantibodies described in 
this thesis, large and well characterised cohorts of dogs with different 
autoimmune manifestations would be required. Dogs with other inflammatory 
but non-autoimmune disorders could also be included as disease controls. A 
limitation of the current work is the lack of clinical data from dogs of other 
breeds besides NSDTRs. Also, the inclusion criteria for IMRD and SRMA were 
quite broad, to facilitate collection of a large enough material. Although the 
veterinary records were assessed by either myself or other veterinarians from our 
research group, different veterinarians investigated the dogs, and different tests 
were used to diagnose and to rule out other causes of disease. Ideally, a 
standardised set of tests should have been performed in all cases, but this was 
not possible due to the retrospective nature of the studies.  
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6.4 Can IMRD be separated into two diseases based on 
the ANA pattern?  
In this thesis, it is shown that the two different sub-phenotypes of IMRD based 
on the ANA pattern correlate with different autoantibodies and different genetic 
risk factors. Some clinical signs also appear to be more common in one of the 
sub-phenotypes; for example, skin lesions are more frequently present in IMRD 
ANAH dogs, which has also been reported previously (Hansson-Hamlin & 
Lilliehöök, 2009). However, in our experience, IMRD cannot clearly be 
separated clinically into two diseases based on the ANA pattern. Autopsies of 
IMRD-affected dogs could potentially reveal different underlying aetiologies or 
pathogenesis, but these dogs are rarely euthanized as a consequence of disease, 
at least not in the acute phase of disease. To predict severity of disease and 
response to treatment is difficult at disease onset, and it would be of value with 
a prognostic marker for IMRD. It needs to be further studied if the ANA pattern, 
or specific autoantibodies, maybe in combination with some genetic risk factors, 
can give insight into the prognosis. In this work patients were subdivided on the 
basis of ANA pattern. Future studies could aim at finding association between 
different genetic variants and specific canine autoantibodies.  
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Ø The overall incidence of disease in NSDTRs is similar to the incidence in 
other retrievers but slightly higher than in all other breeds combined.  
Ø Nova Scotia duck tolling retrievers are predisposed to autoimmune and 
neurological disorders in general and to IMRD and SRMA in particular.  
Ø A particular MHC class II haplotype, DRB1*00601/DQA1*005011/ 
DQB1*02001, is associated with IMRD ANAS. 
Ø A general homozygosity in the MHC class II region is associated with 
IMRD ANAH.  
Ø Eleven genes associated with IMRD and/or SRMA show altered 
functional changes, of which four are associated with only SRMA, one 
with both SRMA and IMRD ANAS, three with both IMRD ANAS and 
IMRD ANAH, and three with only IMRD ANAH.  
Ø Autoantibody reactivity to dsDNA and nucleosomes are associated with 
ANAH. Reactivity to RNP/Sm is associated with ANAS.  
Ø The autoantibody reactivity varies between dogs of different breeds. 
Ø The proteins ILF2 and ILF3 are common autoantigens in ANAS dogs. 
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Immune-mediated diseases are caused by a defective immune system. These are 
common diseases that affect both humans and animals including dogs. Broadly 
they can be divided into immunodeficiency disorders, allergies, and autoimmune 
diseases. The research presented in this thesis primarily focuses on autoimmune 
diseases in dogs. In autoimmune disease, the immune system that is meant to 
protect the body from foreign substances, such as infections, attacks the body’s 
own cells and tissues. This leads to organ damage and clinical signs of disease. 
Dogs of the breed Nova Scotia duck tolling retrievers, often called tollers, are 
affected by an autoimmune disease called immune-mediated rheumatic disease 
(IMRD) and another immune-mediated disease called steroid-responsive 
meningitis-arteritis (SRMA). In Sweden, both these diseases are often referred 
to as “Toller disease”. IMRD affects middle aged dogs. Dogs are often between 
two and six years of age at disease onset. The main clinical signs are lameness 
that can shift between legs, and general stiffness which is often most apparent 
after the dog has been resting. SRMA is a disease primarily affecting young 
dogs. The main clinical signs are high fever and intense neck pain caused by 
meningitis. 
This thesis deals with three different areas; epidemiology (paper I), genetics 
(paper II), and autoantibodies (paper III and IV). In paper I the frequencies of 
different immune-mediated diseases including IMRD and SRMA in tollers were 
studied and compared to the frequencies in other dog breeds. Data were 
assembled from Agria Pet Insurance, which holds information about the cause 
of a dog visiting a veterinarian. In agreement with what has long been suspected, 
but not actually shown before, IMRD, SRMA, and autoimmune disease in 
general were found to be more common in tollers than in other dog breeds 
combined. These diseases were not particularly common even in tollers, 
however. The most common causes for tollers to visit a veterinarian were 
injuries, gastrointestinal disease (such as diarrhoea and vomiting), and clinical 
signs related to the locomotor system (such as lameness). 
Popular science summary 
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It was previously shown that IMRD and SRMA in tollers are complex genetic 
diseases. This means that mutations in several genes cause disease, probably in 
combination with unknown environmental factors. Some regions in the genome 
associated with IMRD or SRMA have been identified. In paper II we present an 
analysis of these regions where we found that genetic variants in 11 genes were 
associated with disease. Most of these genes were associated with only IMRD 
or SRMA, but one gene showed association to both diseases. All the genes are 
good candidates for follow-up studies. Further studies are needed to investigate 
how variations in the genes contribute to disease, and to find the exact disease-
causing mutations.  
Antibodies are an important part of the immune system. In many ways they 
protect the body against infections. In autoimmune diseases the antibodies are 
wrongly directed at the body’s own proteins, which can cause disease. These 
autoantibodies are markers of autoimmune disease and can be used for 
diagnosis. In paper III and IV we aimed at identifying the autoantibody targets 
and to discover new autoantibodies in dogs. We found both new and well-known 
autoantibodies. Two proteins, ILF2 and ILF3, were common targets of 
autoantibodies in IMRD patients. These autoantibodies have not been described 
in dogs previously and have the potential to be used as markers for systemic 
autoimmune disease.  
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Immunmedierade sjukdomar orsakas av defekter i immunsystemet och är 
vanliga sjukdomar hos både människor och djur inklusive hundar. Översiktligt 
kan de delas in i immunbristsjukdomar, allergier och autoimmuna sjukdomar. 
Den forskning som presenteras i denna avhandling berör framförallt 
autoimmuna sjukdomar hos hund. Vid en autoimmun sjukdom attackeras 
kroppens egna celler och vävnader av immunförsvaret, vilket leder till skador på 
organ och kliniska tecken på sjukdom. Hundar av rasen Nova Scotia duck tolling 
retriever (tollare) kan drabbas av en autoimmun sjukdom som kallas 
immunmedierad reumatisk sjukdom (IMRD) och en annan immunmedierad 
sjukdom som heter steroid-responsiv meningit-arterit (SRMA). I Sverige 
benämns ofta båda dessa sjukdomar som tollarsjuka. IMRD drabbar framförallt 
medelålders hundar som oftast är mellan två och sex år när sjukdomen debuterar. 
De vanligaste sjukdomstecknen är hälta som kan vandra mellan olika ben och 
stelhet som oftast är mest tydligt efter att hunden har vilat. SRMA är en typ av 
hjärnhinneinflammation som framförallt drabbar unga hundar. Feber och kraftig 
nacksmärta är de vanligaste tecknen på sjukdom.  
Forskningen som denna avhandling bygger på kan delas in i tre delar; 
epidemiologi (studie I), genetik (studie II) och autoantikroppar (studie III och 
IV). I studie I undersöktes frekvensen av olika immunmedierade sjukdomar hos 
tollare i jämförelse med frekvens hos andra hundraser. Försäkringsdata från 
Agria Djurförsäkringar användes; dessa data innehåller bland annat information 
om orsaker till veterinärbesök. IMRD, SRMA och autoimmuna sjukdomar 
generellt visade sig vara vanligare hos tollare än hos andra hundraser. Det har 
tidigare misstänkts men inte kunnat visas förrän nu. Trots den ökade 
förekomsten hos tollare, var dessa sjukdomar inte särskilt vanliga. De vanligaste 
orsakerna till att en tollare fick veterinärvård var skador, magtarmbesvär (såsom 
kräkningar och diarré) och kliniska tecken kopplade till rörelseapparaten (såsom 
hälta).  
Populärvetenskaplig sammanfattning 
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Det har tidigare visats att IMRD och SRMA är komplexa genetiska 
sjukdomar. Det betyder att mutationer i flera gener, troligtvis tillsammans med 
okända miljöfaktorer, orsakar sjukdom. Flera regioner i arvsmassan som är 
associerade med IMRD och SMRA har hittats. I studie II genomförde vi en 
analys av dessa regioner och fann 11 gener som var associerade med sjukdom. 
De flesta av dessa gener var bara associerade med en av sjukdomarna, men en 
gen var associerad med både IMRD och SRMA. Ytterligare studier behövs för 
att identifiera de specifika sjukdomsorsakande mutationerna och fastställa hur 
dessa verkar för att orsaka sjukdom.  
Antikroppar är en viktig del av immunförsvarets skydd mot infektioner. Vid 
autoimmuna sjukdomar kan antikropparna felaktigt riktas mot kroppens egna 
proteiner. Dessa autoantikroppar är markörer för autoimmun sjukdom och kan 
användas som ett hjälpmedel för att ställa diagnos. Studie III och IV syftade till 
att identifiera de målstrukturer som autoantikropparna är riktade mot och hitta 
nya autoantikroppar hos hund. Vi fann både tidigare beskriva och nya 
autoantikroppar. Autoantikroppar mot två proteiner, ILF2 och ILF3, var vanligt 
förekommande hos hundar med IMRD. Dessa autoantikroppar har inte tidigare 
beskrivits hos hund och har potential att användas som markörer för systemisk 
autoimmun sjukdom.  
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